Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Cash from Operations (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Cash from Operations data on record, last reported at 41125000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations fell 32.41% year-over-year to 41125000.0; the TTM value through Sep 2025 reached 158473000.0, down 64.19%, while the annual FY2024 figure was 119674000.0, 292.0% down from the prior year.
  • Cash from Operations reached 41125000.0 in Q3 2025 per ZBIO's latest filing, up from 41743000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 15400000.0 in Q4 2023 and bottomed at 41743000.0 in Q2 2025.
  • Average Cash from Operations over 3 years is 31874125.0, with a median of 34055000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: plummeted 150.35% in 2024, then crashed 32.41% in 2025.
  • A 3-year view of Cash from Operations shows it stood at 15400000.0 in 2023, then crashed by 150.35% to 38554000.0 in 2024, then dropped by 6.67% to 41125000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 41125000.0 in Q3 2025, 41743000.0 in Q2 2025, and 37051000.0 in Q1 2025.